| Authors: |
Schlenk RF; NCT Trial Center, National Center for Tumor Diseases Heidelberg, Germany richard.schlenk@nct-heidelberg.de.; University Hospital Ulm, Department of Internal Medicine III, Germany., Krauter J; Department of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School, Germany., Raffoux E; Hôpital Saint-Louis - Service d'Hematologie Adulte, Paris, France., Kreuzer KA; Department of Internal Medicine I, University of Cologne, Germany., Schaich M; University of Dresden, Department of Internal Medicine I, Germany., Noens L; Universitair Ziekenhuis, Gent, Belgium., Pabst T; Inselspital, Bern, Switzerland., Vusirikala M; University of Texas Southwestern Medical Center, Dallas, TX, USA., Bouscary D; Hôpital Cochin, Paris, France., Spencer A; The Alfred Hospital, Melbourne, VIC, Australia., Candoni A; Azienda Ospedaliero-Universitaria 'Santa Maria della Misericordia' di Udine, Italy., Gil JS; Hospital de la Santa Creu i Sant Pau, IIB Sant Pau and Jose Carreras Research Institutes, Barcelona, Spain., Berkowitz N; Novartis Pharmaceutical Corporation, East Hanover, NJ, USA., Weber HJ; Novartis Pharma AG, Basel, Switzerland., Ottmann O; University of Frankfurt, Department of Internal Medicine II, Germany. |
